Telix Showcases Pivotal Cancer Trials and Next-Gen Theranostics at EANM Congress

  • Telix will present 20 abstracts at the EANM Congress in Vienna from October 17-21, 2026, including 12 oral presentations.
  • Key trials highlighted include Phase 3 studies for TLX101-Tx in glioblastoma, TLX250-Tx in ccRCC, and interim results for TLX597-Tx in prostate cancer.
  • Topline Phase 3 data for TLX591-Px (Illuccix) PET imaging in Chinese men will be presented.
  • Telix will host a sponsored symposium on the future of theranostics in urologic oncology.

Telix's strong presence at the EANM Congress underscores its leadership in the theranostics space, particularly in prostate, brain, and renal cancers. The company's focus on next-generation technologies and precision diagnostics aligns with the broader industry trend towards personalized medicine and targeted cancer therapies. The strategic emphasis on expanding its commercial franchise and deepening its pipeline positions Telix to capitalize on the growing demand for advanced radiopharmaceutical solutions.

Clinical Trial Success
Whether the Phase 3 trial results for TLX101-Tx, TLX250-Tx, and TLX597-Tx will meet regulatory standards for approval.
Market Expansion
The pace at which Telix can expand the commercial use of Illuccix in global markets beyond the current 22 countries.
Technological Integration
How Telix's AI and MedTech innovations, such as QDOSE dosimetry software, will enhance the precision and efficiency of theranostic treatments.